Older women with breast cancer report better cosmetic satisfaction with less radiation, less surgery

Reduced radiation was associated with slight risk of recurrence

MD Anderson News Release December 09, 2016

 In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The University of Texas MD Anderson Cancer Center researchers found that less radiation was associated with improved cosmetic satisfaction long-term. However, reduced radiation was also associated with a slightly increased risk of disease recurrence.                              

The findings, presented at the 2016 San Antonio Breast Cancer Symposium in a poster session by Cameron W. Swanick, M.D., should serve as an important discussion point between older patients and their physicians when making treatment decisions. 

Like younger patients, older women with early stage breast cancer often have a number of treatment options, including: lumpectomy and whole breast irradiation (Lump + WBI); lumpectomy plus brachytherapy (Lump + Brachy); lumpectomy alone (Lump alone); mastectomy without radiation (Mast alone); and mastectomy plus radiation (Mast +RT).  However, cosmetic and other quality of life outcomes associated with these treatment options have not been compared in this age population.

“There’s very little in the literature regarding older patient-reported outcomes -- either they were not included in previous studies, or were not asked about their cosmetic satisfaction. With our study, we wanted to survey women to better understand their long-term cosmetic satisfaction, and compare satisfaction across local therapy strategies,” says Swanick, resident, Radiation Oncology.

The study builds on research published in 2012 by Benjamin D. Smith, M.D., which found that accelerated partial breast irradiation (APBI) brachytherapy is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional WBI.

“Despite the findings, brachytherapy advocates felt strongly that patients were happy with their outcomes. It was important for us to take a different methodology to learn from the patient experience and determine their preferences,” says Smith, associate professor, Radiation Oncology. 

Swanick and Smith used Medicare claims to prospectively identify women 67 or older and diagnosed with non-metastatic breast cancer in 2009. The women must have received one of five treatment options and were alive in 2015. From this cohort, 1,650 patients (330 patients per local therapy) were randomly selected. Potential participants were mailed a survey designed using several validated instruments to assess cosmetic satisfaction in breast cancer patients.

A total of 498 women (30 percent) responded to the survey. The median age was 73 years old. The primary endpoint was satisfaction with cosmetic outcome.

Using Lump +WBI as the reference group, as it’s the most widely accepted as standard of care, cosmetic satisfaction scores were higher for Lump + Brachy and Lump alone. Looking at the two mastectomy groups, patients who had Mast +RT reported significantly worse cosmetic outcomes compared to Lump and WBI. There was no difference between Lump + WBI and Mast alone in this cohort.

Patients also reported if their breast cancer had recurred. A small but statistically significant number of patients, six percent, reported recurrences in the Lump + Brachy and Lump alone cohort, compared to patients treated with Lump and WBI.

Given their previous findings, the researchers were surprised that Lump + Brachy performed so well, but noted the higher incidence of recurrence. These findings show that, overall, the less radiation given, the better for the long-term cosmetic satisfaction of the patient, say the researchers.

“We need treatment that is gentler than whole breast radiation, but provides broader of coverage than brachytherapy,” says Smith. “There are plenty of hints in the literature that indicate there’s a happy medium in between these two treatments, and that’s probably the sweet spot for many breast cancer patients.”

To that goal, Smith is launching a radiation study looking at two-to- two-and-a-half weeks of treatment of external beam treating a large area surrounding the tumor bed.

“These are important data to discuss with patients, because some women may accept a higher local recurrence risk in exchange change for better cosmetic satisfaction,” says Swanick.

The researchers are developing a decision making tool for elderly breast cancer patients.

In addition to Swanick and Smith, other MD Anderson authors on the study include: Sharon Giordano, M.D., Xiudong Lei, Ph.D., and Ying Xu, M.D., all of Health Services Research; Yu Shen, Ph.D.; Biostatistics; Susan K. Peterson, Ph.D. and Nathan A. Goodwin, both of Behavioral Science; Kelly Hunt, M.D., Breast Surgical Oncology and Simona F. Shaitelman, M.D., Radiation Oncology. Reshma Jagsi, M.D., D.Phil of the University of Michigan Health System, also is an author on the study.

The study was funded by an MD Anderson Survivorship IRG Grant and ASTRO Comparative Effectiveness Research Grant.